L.M. Sarmasti

发表

PHASE I/II STUDY OF UMBRALISIB (TGR‐1202) IN COMBINATION WITH UBLITUXIMAB (TG‐1101) AND PEMBROLIZUMAB IN PATIENTS WITH REL/REF CLL AND RICHTER'S TRANSFORMATION

A. Zelenetz, E. L. Luning Prak, D. Brander, 2019, Hematological Oncology.